Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is studying biomarkers in predicting response to rituximab treatment in samples from patients with indolent follicular lymphoma.
Genetic: DNA analysis
Genetic: gene expression analysis
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
Other: medical chart review
|Official Title:||Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods|
- Correlation of FCGR3A 158V/F polymorphisms with response, duration of response, and time to rituximab resistance
- Copy number variation in FCGR3A cohort [ Designated as safety issue: No ]
|Study Start Date:||June 2011|
|Estimated Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
- Genotype the full cohort of samples available from the RESORT clinical trial (ECOG-E4402) for FCGR3A 158V/F in parallel to independently verify results.
- Correlate the FCGR3A 158V/F polymorphisms to response, response duration, and time to rituximab resistance.
- Quantify copy number variation in FCGR3A in this cohort.
OUTLINE: Archived DNA samples isolate from peripheral blood mononuclear cells and from formalin-fixed paraffin-embedded tissue samples are analyzed for FCGR3A 158V/F polymorphisms using different complementary genotyping methods. Assay results are reviewed and compared with patients' outcome data.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01381705
|Principal Investigator:||Brad S. Kahl, MD||University of Wisconsin, Madison|